Diffuse large B-cell lymphoma: a single disease?
Non-Hodgkin’s lymphomas are common and comprise a heterogeneous group of neoplasms, with diffuse large B-cell lymphoma (DLBCL) accounting for more than 60% of cases. Moreover, DLBCL presents with a variety of clinical characteristics, genetic profiles, and therapeutic responses. We aimed to improve...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Instituto Nacional de Salud
2017-10-01
|
| Series: | Revista Peruana de Medicina Experimental y Salud Pública |
| Subjects: | |
| Online Access: | https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/2803 |
| Summary: | Non-Hodgkin’s lymphomas are common and comprise a heterogeneous group of neoplasms, with diffuse large B-cell lymphoma (DLBCL) accounting for more than 60% of cases. Moreover, DLBCL presents with a variety of clinical characteristics, genetic profiles, and therapeutic responses. We aimed to improve progression-free survival, total survival, and objective results in an DLBCL subgroup. However, another subgroup demonstrated poor responses. Therefore, it is necessary to design treatment programs based on clinical, immunohistochemical, and genetic profiles, grouping cases properly to identify correct therapeutic modalities for each lymphoma subtype. Currently, these neoplasms are classified as high- and low-risk lymphomas, and therapeutic regimens are being developed to complement conventional R-CHOP, such as R-DA-EPOCH, R2CHOP, IR-CHOP, VR-CHOP, and eveRCHOP, which are expected to improve outcomes. |
|---|---|
| ISSN: | 1726-4634 1726-4642 |